Trial Profile

CIRG (TRIO) 011/NSABP B-44-I / B020906: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Acronyms BETH
Sponsors Roche

19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
05 Oct 2021 This trial has been completed in Spain (End Date: 17 Apr 2014), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com